Valuation Neuland Laboratories Limited NSE India S.E.
Stocks
NEULANDLAB
INE794A01010
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22,216.00 INR | -2.80% |
|
+12.91% | +46.40% |
| 08-05 | Neuland Laboratories Limited, Q1 2027 Earnings Call, Aug 05, 2026 | |
| 08-05 | Neuland Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Company Valuation: Neuland Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 13,171 | 23,087 | 80,588 | 154,946 | 154,121 | 293,080 | - | - |
| Change | - | 75.28% | 249.07% | 92.27% | -0.53% | 90.16% | - | - |
| Enterprise Value (EV) 1 | 13,171 | 23,087 | 80,374 | 153,929 | 153,584 | 295,641 | 294,060 | 290,784 |
| Change | - | 75.28% | 248.14% | 91.52% | -0.22% | 92.49% | -0.54% | -1.11% |
| P/E | 20.6x | 14.1x | 26.9x | - | 42.3x | 61.3x | 47x | 34.5x |
| PBR | 1.58x | - | 6.32x | 10.2x | 8.27x | 12.7x | 10.2x | 8.12x |
| PEG | - | 0x | 0.3x | - | - | 2x | 1.5x | 1x |
| Capitalization / Revenue | 1.38x | 1.94x | 5.17x | 10.5x | 7.62x | 12x | 10x | 8.46x |
| EV / Revenue | 1.38x | 1.94x | 5.16x | 10.4x | 7.59x | 12.1x | 10x | 8.39x |
| EV / EBITDA | 9.24x | 8.49x | 17.4x | 47.6x | 26.7x | 40.4x | 31.1x | 24.5x |
| EV / EBIT | 14.1x | - | 19.9x | 59.7x | 31.8x | 46.1x | 34.9x | 27.5x |
| EV / FCF | -35.3x | 13.5x | 68.4x | 139x | -304x | 66.2x | 72.7x | 48.4x |
| FCF Yield | -2.83% | 7.41% | 1.46% | 0.72% | -0.33% | 1.51% | 1.38% | 2.07% |
| Dividend per Share 2 | - | 10 | 14 | 12 | 34 | - | 46.3 | 56.9 |
| Rate of return | - | 0.56% | 0.22% | 0.1% | 0.28% | - | 0.2% | 0.25% |
| EPS 2 | 49.74 | 127.4 | 233.9 | - | 283.7 | 372.7 | 486.5 | 661.4 |
| Distribution rate | - | 7.85% | 5.99% | - | 12% | - | 9.52% | 8.6% |
| Net sales 1 | 9,511 | 11,912 | 15,586 | 14,768 | 20,230 | 24,419 | 29,283 | 34,642 |
| EBITDA 1 | 1,426 | 2,718 | 4,626 | 3,233 | 5,745 | 7,321 | 9,460 | 11,884 |
| EBIT 1 | 935.8 | - | 4,029 | 2,577 | 4,828 | 6,409 | 8,437 | 10,566 |
| Net income 1 | 638.2 | 1,635 | 3,001 | 2,601 | 3,640 | 4,798 | 6,265 | 8,532 |
| Net Debt 1 | - | - | -214.1 | -1,017 | -536.9 | 2,561 | 979.4 | -2,296 |
| Reference price 2 | 1,026.60 | 1,799.45 | 6,281.30 | 12,076.95 | 12,012.65 | 22,843.55 | 22,843.55 | 22,843.55 |
| Nbr of stocks (in thousands) | 12,830 | 12,830 | 12,830 | 12,830 | 12,830 | 12,830 | - | - |
| Announcement Date | 5/10/22 | 5/11/23 | 5/10/24 | 5/15/25 | 5/12/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.6x | 12.3x | 24.81x | 0.58% | 1,057B | |
| 28.84x | - | - | 2.07% | 625B | |
| 32.43x | 7.35x | 15.3x | 2.81% | 435B | |
| 20.47x | 4.85x | 12.02x | 2.72% | 363B | |
| 22.14x | 5.72x | 14.28x | 2.8% | 296B | |
| 20.58x | 4.25x | 12.07x | 2.07% | 249B | |
| 25.76x | 6.78x | 12.06x | 2.45% | 222B | |
| 13.84x | 4.97x | 10.44x | 3.68% | 209B | |
| -41.37x | 5.93x | 33.46x | 2.47% | 165B | |
| Average | 17.37x | 6.52x | 16.80x | 2.41% | 402.31B | |
| Weighted average by Cap. | 24.45x | 8.09x | 18.31x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- NEULANDLAB Stock
- NEULANDLAB Stock
- Valuation Neuland Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
